Department of Psychology, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.
Department of Psychology, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.
Neuroscience. 2018 Oct 15;390:241-255. doi: 10.1016/j.neuroscience.2018.08.028. Epub 2018 Sep 1.
Adult neurogenesis has potential to ameliorate a number of disorders that negatively impact the hippocampus, including age-related cognitive decline, depression, and schizophrenia. A number of treatments enhance adult neurogenesis including exercise, NMDA receptor antagonism, antidepressant drugs and environmental enrichment. Despite the chronic nature of many disorders, most animal studies have only examined the efficacy of neurogenic treatments over short timescales (≤1 month). Also, studies of neurogenesis typically include only 1 sex, even though many disorders differentially impact males and females. We tested whether two known neurogenic treatments, running and the NMDA receptor antagonist, memantine, could cause sustained increases in neurogenesis in male and female rats. We found that continuous access to a running wheel (cRUN) initially increased neurogenesis, but effects were minimal after 1 month and completely absent after 5 months. Similarly, a single injection of memantine (sMEM) transiently increased neurogenesis before returning to baseline at 1 month. To determine whether neurogenesis could be increased over a 2-month timeframe, we next subjected rats to interval running (iRUN), multiple memantine injections (mMEM), or alternating blocks of iRUN and mMEM. Two months of iRUN increased DCX cells in females and iRUN followed by mMEM increased DCX cells in males, indicating that neurogenesis was increased in the later stages of the treatments. However, thymidine analogs revealed that neurogenesis was minimally increased during the initial stages of the treatments. These findings highlight temporal limitations and sex differences in the efficacy of neurogenic manipulations, which may be relevant for designing plasticity-promoting treatments.
成人神经发生有可能改善许多对海马体产生负面影响的疾病,包括与年龄相关的认知能力下降、抑郁和精神分裂症。许多治疗方法可以增强成人神经发生,包括运动、NMDA 受体拮抗剂、抗抑郁药和环境丰富。尽管许多疾病具有慢性性质,但大多数动物研究仅在短时间内(≤1 个月)检查了神经发生治疗的疗效。此外,神经发生的研究通常只包括 1 种性别,尽管许多疾病对男性和女性的影响不同。我们测试了两种已知的神经发生治疗方法,即跑步和 NMDA 受体拮抗剂美金刚,是否可以在雄性和雌性大鼠中持续增加神经发生。我们发现,持续使用跑步轮(cRUN)最初会增加神经发生,但 1 个月后效果很小,5 个月后完全消失。同样,单次注射美金刚(sMEM)会短暂增加神经发生,然后在 1 个月时恢复到基线。为了确定是否可以在 2 个月的时间内增加神经发生,我们接下来让大鼠进行间歇跑步(iRUN)、多次美金刚注射(mMEM)或 iRUN 和 mMEM 交替进行。2 个月的 iRUN 增加了雌性大鼠的 DCX 细胞,而 iRUN 后进行 mMEM 则增加了雄性大鼠的 DCX 细胞,表明神经发生在治疗的后期增加。然而,胸苷类似物表明,在治疗的初始阶段,神经发生的增加很少。这些发现突出了神经发生干预的时间限制和性别差异,这可能与设计促进可塑性的治疗方法有关。